COMPANION DIAGNOSTICS MARKET ANALYSIS

Companion Diagnostics Market, By Technology Type (Real Time-Polymerase Chain Reactions (PCR), Gene Sequencing, Fluorescence in situ Hybridization, and Others) By Application (Oncology, Cardiovascular Diseases, Infectious Diseases, Neurological Diseases and Others), By End User (Hospitals, Research Laboratories, Biopharmaceutical companies, and Others), By Region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa)

Recent Developments

New product launches/ Approvals

On August 7, 2023, QIAGEN, a molecular diagnostics company, received U.S. Food and Drug Administration (FDA) approval of its therascreen PDGFRA RGQ PCR kit. The kit is the first platelet-derived growth factor receptor alpha (PDGFRA) assay to receive U.S. Food and Drug Administration (FDA) approval as a companion diagnostic
On August 2022, Thermo Fisher Scientific Inc. a biotechnology company received U.S. Food and Drug Administration (FDA) grant premarket approval for Oncomine Dx Target Test as a companion diagnostic (CDx) to identify patients whose tumors have a HER2 (ERBB2) activating mutations in non-small cell lung cancer

Acquisition and partnerships

In October 26, 2023, QIAGEN a molecular diagnostics company and Myriad Genetics a genomic testing company enter into strategic partnership to develop companion diagnostic tests in the field of cancer. This partnership covers development of lab-developed and distributable kit-based companion diagnostic tests.
In January 2022, Illumina Inc. a biotechnology company entered into strategic partnership with Boehringer Ingelheim a pharmaceutical company to develop companion diagnostics (CDx) for several programs in Boehringer Ingelheim's oncology pipeline. This partnership accelerates the development of therapy selection and precision medicines for patients with advanced cancer.